A Phase 1 interventional study of TP-3654 in Myelofibroses, sponsored by Sumitomo Pharma America, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 453 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 259th largest by enrollment of the 387 interventional ones that give a count, is one of 16 that started in 2024, is one of 117 in phase 1, and was the 445th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →70 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
453 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 166 · Phase 2 219 · Phase 3 45
First in 1992; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 387 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 453 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 2 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 453 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will determine the bioavailability and effect of food on TP-3654 in healthy adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized, single-dose, 3-period, 3-way cross-over study to assess the relative bioavailability of TP-3654 capsule formulation (1:5 ratio of API:excipient) vs capsule formulations using a 1:3 and 1:2 of API:excipient ratio.
Drug: TP-3654
Randomized, single-dose, 3-period, 3-way cross-over study to evaluate the effect of food on the PK of the Sponsor's selected TP-3654 capsule formulation (1:3 or 1:2).
Drug: TP-3654
capsule, oral administered
The Cmax for relative bioavailability of TP-3654 in Part A
Analysis of the maximum concentration (Cmax) of the relative bioavailability of TP-3654 in two different capsule formulations utilizing the ratio of adjusted geometric means
Time frame: 13 days
The Cmax for relative bioavailability of TP-3654 in Part B
Analysis of the maximum concentration (Cmax) of the relative bioavailability of the selected capsule formulation of TP-3654 from Part A when administered in fed versus fasting conditions utilizing the ratio of adjusted geometric means.
Time frame: 13 days
The AUC for relative bioavailability of TP-3654 in Part A
Analysis of the area under the concentration (AUC) time curve of the relative bioavailability of TP-3654 in two different capsule formulations utilizing the ratio of adjusted geometric means
Time frame: 13 days
The AUC for relative bioavailability of TP-3654 in Part B
Analysis of the area under the concentration (AUC) time curve of the relative bioavailability of the selected capsule formulation of TP-3654 from Part A when administered in fed versus fasting conditions utilizing the ratio of adjusted geometric means.
Time frame: 13 days
The number of adverse events and their severity as reported in healthy adult participants
Time frame: 47 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in May 2024, 2 months.
Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TP 3654
Sumitomo Pharma America, Inc. →